A5015707456- CAR-T cell therapy research
- Hematopoietic Stem Cell Transplantation
- Lymphoma Diagnosis and Treatment
- Acute Lymphoblastic Leukemia research
- Chronic Lymphocytic Leukemia Research
- Chronic Myeloid Leukemia Treatments
- Acute Myeloid Leukemia Research
- Polyomavirus and related diseases
- Immunotherapy and Immune Responses
- Renal Transplantation Outcomes and Treatments
- Biosimilars and Bioanalytical Methods
- Immune Cell Function and Interaction
- Cytomegalovirus and herpesvirus research
- T-cell and B-cell Immunology
- Multiple Myeloma Research and Treatments
- Viral Infectious Diseases and Gene Expression in Insects
- Integrated Circuits and Semiconductor Failure Analysis
- T-cell and Retrovirus Studies
- Virus-based gene therapy research
- Viral-associated cancers and disorders
- Histone Deacetylase Inhibitors Research
- Childhood Cancer Survivors' Quality of Life
- Advancements in Semiconductor Devices and Circuit Design
- Cancer survivorship and care
- COVID-19 Clinical Research Studies
Moffitt Cancer Center
2016-2025
University of South Florida
2017-2023
Cook Children's Medical Center
2022
West Virginia University
2009-2019
West Virginia University Hospitals
2013
Aga Khan University Hospital
2007-2008
Aga Khan University
2007
CD19 CAR T-cell therapy with axicabtagene ciloleucel (axi-cel) for relapsed or refractory (R/R) large B cell lymphoma (LBCL) may lead to durable remissions, however, prolonged cytopenias and infections occur. In this single center retrospective study of 85 patients, we characterized immune reconstitution patients remaining in remission after axi-cel LBCL. Prolonged (those occurring at day 30 following infusion) were common >= grade 3 neutropenia seen 21/70 (30-0%) persisting 3/31 (9-7%) 1...
Abstract High metabolic tumor volume (MTV) predicts worse outcomes in lymphoma treated with chemotherapy. However, it is unknown if this holds for patients axicabtagene ciloleucel (axi-cel), an anti-CD19 targeted chimeric antigen receptor T-cell therapy. The primary objective of retrospective study was to investigate the relationship between MTV and survival (overall [OS] progression-free [PFS]) relapsed/refractory large B-cell (LBCL) axi-cel. Secondary objectives included finding...
Hematopoietic cell transplantation (HCT) is curative for hematologic disorders, but outcomes are historically inferior when using HLA-mismatched donors. Despite unrelated donor registries listing > 38 million volunteers, 25%-80% of US patients lack an HLA-matched donor, with significant disparity across ethnic groups. We hypothesized that HCT a mismatched (MMUD) post-transplant cyclophosphamide (PTCy), novel strategy successful in overcoming genetic related donors, would be feasible and...
PURPOSEAccess to allogeneic hematopoietic cell transplantation (HCT) remains limited among persons of non-European ancestry if human leukocyte antigen (HLA) matching is required. We evaluated whether post-transplant cyclophosphamide (PTCy)-based graft-versus-host disease (GVHD) prophylaxis improved HCT outcomes with HLA-matched unrelated donor (MUD) and mismatched (MMUD) when compared calcineurin inhibitor (CNI)-based prophylaxis.METHODSThree-year overall survival (OS) GVHD-free,...
Idecabtagene vicleucel (ide-cel) was FDA-approved in March 2021 for the treatment of relapsed/refractory multiple myeloma after 4 lines therapy. On KarMMa trial, grade ≥ 3 cytopenias and infections were common. We sought to characterize within 100 days ide-cel standard-of-care (SOC) setting. This multi-center retrospective study included 52 patients who received SOC ide-cel; 47 reached day-90 follow-up. Data censored at day 100. Grade cytopenia present among 65% 30 40% 90. Granulocyte colony...
<h3>Importance</h3> Primary central nervous system lymphoma (PCNSL) requires induction and consolidation to achieve potential cure. High-dose therapy autologous hematopoietic cell transplant (AHCT) is an accepted effective strategy for PCNSL, but no consensus exists on the optimal conditioning regimens. <h3>Objective</h3> To assess outcomes in patients with PCNSL undergoing AHCT 3 most commonly used regimens: thiotepa/busulfan/cyclophosphamide (TBC), thiotepa/carmustine (TT-BCNU),...
Fifty years have passed since the development of first chemotherapy regimen for treating acute myelogenous leukemia (AML), with approval in 1973 cytarabine daunorubicin (7+3) regimen. Until recently, patients diagnosed AML had very limited treatment options and depended primarily on combinations, doses, or schedules same drugs. Patients advanced age, comorbidities, relapsed refractory disease were left no effective treatment. New advances understanding biology molecular genetic changes...
A subset of patients with diffuse large B-cell lymphoma (DLBCL) treated CD19 chimeric antigen receptor (CAR) T-cell therapy have poor clinical outcomes. We report serum proteins associated severe immune-mediated toxicities and inferior responses in 146 DLBCL axicabtagene ciloleucel. develop a simple stratification based on pre-lymphodepletion C reactive protein (CRP) ferritin to classify into low-, intermediate-, high-risk groups. observe that the category were more likely grade ≥3 had...
One of the challenges adoptive T-cell therapy is development immune-mediated toxicities including cytokine release syndrome (CRS) and neurotoxicity (NT). We aimed to identify factors that place patients at high risk severe toxicity or treatment-related death in a cohort 75 with large B-cell lymphoma treated standard care CD19 targeted CAR product (axicabtagene ciloleucel).Serum catecholamine levels were measured prior lymphodepleting chemotherapy, on day T infusion daily thereafter while...
The use of post-transplantation cyclophosphamide (PTCy) as graft-versus-host disease (GVHD) prophylaxis has resulted in reductions GVHD and improved outcomes allogeneic hematopoietic cell transplantation (HCT) using HLA-mismatched related donors. We report the 3-year first multicenter prospective clinical trial PTCy setting mismatched unrelated donor (MMUD) bone marrow HCT. study enrolled 80 patients, treated with either myeloablative conditioning (MAC; n = 40) or reduced-intensity (RIC;...
Abstract Background Chimeric antigen receptor T- Cell (CAR-T) immunotherapy has been a breakthrough treatment for various hematological malignancies. However, cardiotoxicities such as new-onset heart failure, arrhythmia, acute coronary syndrome and cardiovascular death occur in 10–15% of patients treated with CAR-T. This study aims to investigate the changes cardiac inflammatory biomarkers CAR-T therapy determine role pro-inflammatory cytokines. Methods In this observational study, ninety...
Abstract In patients with relapsed DLBCL in complete remission (CR), autologous hematopoietic cell transplantation (auto-HCT) and CAR-T therapy are both effective, but it is unknown which modality provides superior outcomes. We compared the efficacy of auto-HCT vs. a CR. A retrospective observational study comparing (2015–2021) (2018–2021) using Center for International Blood & Marrow Transplant Research registry. Median follow-up was 49.7 months 24.7 cohort. Patients ages 18 75...
The subject of economic migration among health care professionals has received intense attention. However, the aetiology this not been rigorously evaluated in Pakistan. Such knowledge can potentially influence and academic policies. Our current study proposes to quantify relative contributions various personal, professional variables final-year medical students Karachi.A self-administered structured questionnaire using a 10-point scale was developed piloted Karachi students. Additional...
Abstract The introduction of posttransplant cyclophosphamide (PTCy) made performing allogeneic hematopoietic cell transplantation (HCT) from HLA haplotype–incompatible donors possible. In a setting PTCy and tacrolimus/mycophenolate mofetil (MMF) as graft-versus-host disease (GVHD) prophylaxis, peripheral blood (PB) graft source compared with bone marrow reduces the relapse rate but increases acute GVHD (aGVHD) chronic (cGVHD). This phase 2 trial assessed sirolimus MMF efficacy following...
Post-transplantation cyclophosphamide (PTCy) is being increasingly used for graft-versus-host disease (GVHD) prophylaxis after allogeneic hematopoietic cell transplantation (allo-HCT) across various donor types. However, immune reconstitution and infection incidence PTCy-based versus conventional GVHD has not been well studied. We evaluated the density (ie, absolute CD4+ T cell, CD8+ natural killer B counts) at 3 months, 6 1 year post-HCT in 583 consecutive adult patients undergoing allo-HCT...
Abstract Idecabtagene vicleucel (ide-cel) is a type of B-cell maturation antigen (BCMA)–targeting chimeric receptor T-cell (CAR-T) approved for the treatment relapsed and refractory multiple myeloma (RRMM). Currently, incidence cardiac events associated with ide-cel remains unclear. This was retrospective single-center observational study patients treated RRMM. We included all consecutive who received standard-of-care at least 1-month follow-up. Baseline clinical risk factors, safety...
Background: Previous studies have shown that allogeneic peripheral blood stem cell transplantation (PBSCT) from an HLA haploidentical (haplo) donor followed by graft-versus-host disease (GVHD) prophylaxis with post-transplant cyclophosphamide (PTCy) results in lower relapse rates and improved DFS when compared to haplo bone marrow transplant (BMT) PTCy. However, PBSCT leads higher of GVHD. It is unknown whether the benefits may be nullified older patients (>60 years) a susceptibility GVHD...
PURPOSE This phase I-Ib trial evaluated a novel CD40L blocking antibody, BMS-986004, for the prevention of graft-versus-host disease (GVHD) after unrelated donor allogeneic hematopoietic cell transplantation (HCT). PATIENTS AND METHODS A total 34 patients were treated at three centers. The safety and biologic activity single-dose BMS-986004 (675 mg [n = 6] 1,500 6]; one-time dose) evaluated. Safety prolonged dosing was then examined in separate cohorts (drug administration every 2 weeks × 3...
"TIP25-246: Evaluating the Effect of a Mindfulness-Based Intervention on Metabolic and Immunological Biomarkers Stress Among Caregivers Allogeneic Hematopoietic Stem Cell Transplant Recipients: Trial in Progress" published 28 Mar 2025 by National Comprehensive Cancer Network.